Skip to main content
. 2013 Nov 4;347:f6153. doi: 10.1136/bmj.f6153

Table 11.

 Initial response and recurrence of SCCs after photodynamic therapy

Study No of SCCs Initial assessment after treatment Proportion (95% CI) with apparent complete response Proportion (95%CI) of SCCs with recurrence after apparent complete response Duration of follow-up Comments
Topical photosenstitiser
Baptista 2006 4 1 month 0.25 (0.01 to 0.80) 0.00 (0.00 to 0.98), n=1 Median 38 months
Calzavara-Pinton 1995 6 nodular, 12 superficial 1 month 0.5 (0.12 to 0.88), 0.83 (0.52 to 0.98) 0.50 (0.01 to 0.99), n=2; 0.00 (0.00 to 0.71), n=3 29 months (24-36). Residual tumour in 1 of 2 biopsied apparently responsive nodular SCCs, and in 1 of 8 biopsied responsive superficial SCCs
Calzavara-Pinton 2008 40 microinvasive, 31 invasive 3 months 0.8 (0.64 to 0.91), 0.45 (0.27 to 0.64) 0.28 (0.14 to 0.47), n=32; 0.43 (0.18 to 0.71), n=14 ≤24 months
Fink-Puches 1998 35 2-4 weeks 0.54 (0.37 to 0.71) 0.69 (0.41 to 0.89), n=16 Median 8 months (range 3-47)
Fritsch 1998 36 Not specified 0.75 (0.58 to 0.88)
Haddad 2004 43 21 days 0.74 (0.59 to 0.86)
Harth 1998 5 Not specified 0.8 (0.28 to 0.99)
Kennedy 1990 2 “elevated,” 6 “early invasive” 2–3 months 0.00 (0.00 to 0.84), 1.0 (0.54 to 1.0)
Lui 1995 2 3 months 0.00 (0.00 to 0.84)
Wolf 1993 6 4 and/or 8 weeks 0.83 (0.36 to 1.0) 0.00 (0.00 to 0.52), n=5 7 months (range 3-12)
Ziokolwski 2004 11 (no glycolic acid), 12 (plus glycolic acid) Not specified 0.64 (0.31 to 0.89), 1.0 (0.74 to 1.0) “Complete response” at 12 months “Complete response” defined as no clinically visible or 5-ALA fluorescence detectable tumour after 12 months of observation
Systemic photosensitiser
Feyh 1990 5 2 months 1.0 (0.48 to 1.0) 0.00 (0.00 to 0.52), n=5 Maximum 14 months
Kubler 1999 9 3 months 1.0 (0.66 to 1.0) 0.00 (0.00 to 0.34), n=9 Mean 20 months (range 8-24)
Pennington 1988 32 6 weeks 0.81 (0.64 to 0.93) 0.5 (0.32 to 0.68), n=32 6 months Authors found no correlation between recurrence and presence of residual tumour on histology at initial assessment, and abandoned trial in view of results